November 27, 2025 - We now made available the NH-TNE Teaching on Neonatal Hypertension by Dr. Joseph Mancini (Nephrologist at the Montreal Children’s Hospital) recorded on November 27, 2025. In this educational lecture, Dr. Mancini reviews: Definition and thresholds of neonatal hypertension; Common causes and risk factors in preterm and term infants; Diagnostic workup and blood pressure measurement best practices; Acute vs. chronic management strategies; Collaborative approach between neonatology, nephrology, cardiology & hemodynamics teams. This session is part of the NeoCardioLab educational series dedicated to advancing neonatal hemodynamics practice through shared knowledge and accessible training materials. Slides available as PDF as well.
Some preterm infants—particularly those with bronchopulmonary dysplasia (BPD)—may develop significant systemic hypertension, defined as blood pressure exceeding the 95th percentile for postmenstrual age (as per established references - Dionne et al.). This condition may result from a combination of elevated systemic vascular resistance (SVR), prior acute kidney injury, increased vascular stiffness, or exposure to corticosteroids. Systemic hypertension can contribute to left ventricular (LV) remodeling, increased LV stiffness, ongoing adaptation with LV hypertrophy and elevated left ventricular end-diastolic pressure (LVEDP), which may subsequently raise left atrial (LA) pressure and impair pulmonary venous drainage—thereby exacerbating pulmonary vascular disease. Indeed, Laplace's law, in the context of the heart, explains how the heart compensates for increased workload through hypertrophy. When the heart faces increased afterload (like from high blood pressure / high systemic vascular resistances) or volume overload, it responds by thickening its walls (hypertrophy). This thickening, according to Laplace's law, helps to normalize the stress on the heart muscle caused by the increased pressure or volume. However, this adaptation has limits, and excessive hypertrophy can lead to heart failure
When evaluating the right ventricular (RV)/pulmonary arterial compartment in relation to the LV/aortic compartment, whether through septal morphology or shunt directionality (e.g., across post-tricuspid defects), it is essential to interpret findings within the broader context of systemic hemodynamics. Elevated systemic blood pressure may lead to underestimation or mischaracterization of pulmonary hypertension (PH). For example, an infant may have elevated RV and pulmonary artery pressures, but the LV may appear round at peak systole—suggestive not of low RV afterload, but of concurrent systemic hypertension. Similarly, a VSD or PDA may shunt left to right because of high systemic vascular resistance relative to pulmonary vascular resistances (even if the PVR and/or PA pressures are elevated). As such, a right to left post-tricuspid shunt may not be present, despite elevated PVR and/or RV/PA pressures in the setting of high SVR and/or LV/PA pressures.
Similarly, the right ventricle (RV) may be exposed to elevated afterload with associated remodeling and reduced compliance. Concurrently, the LV may exhibit hypertrophy and diastolic dysfunction secondary to systemic hypertension, resulting in even greater impairment in LV compliance. In this setting, a left-to-right shunt at the atrial level may persist or become more prominent, despite elevated right ventricular end-diastolic pressure (RVEDP), due to the relatively higher left atrial pressures driven by impaired LV filling. As such, the expected bidirectional or right ot left shunting at the atrial level may not be present. This paradox underscores the importance of comprehensive assessment of biventricular relaxing/filling properties, shunt physiology, and systemic hemodynamics when interpreting TnECHO findings in infants with complex cardiopulmonary interactions.
In patients with suspected or confirmed systemic hypertension, early involvement of nephrology is advised. Evaluation should include abdominal ultrasound with renal Doppler to assess for renovascular pathology, and serial monitoring of renal biomarkers and electrolytes (plasma and urine creatinine, urine and serum electrolytes). Antihypertensive therapy should be tailored to the clinical context, with agents such as angiotensin-converting enzyme (ACE) inhibitors (e.g., enalapril) and diuretics (e.g., hydrochlorothiazide, spironolactone) considered based on renal function, volume status, and hemodynamic profile.
Anti-Hypertensive Medications can be found in the Cardiovascular Agents section.
What are the causes of hypertension in neonates?Similar to the causes of hypertension in pediatric population with few additional differential specific for this age.
Renal: Renal artery thrombosis (particularly if a UAC has been in place); renal vein thrombosis; renal artery stenosis or compression (e.g., from tumor or post–tight abdominal wall closure); parenchymal renal disease – congenital (ARPKD, ADPKD) or acquired (acute tubular necrosis from poor perfusion, e.g., sepsis, asphyxia); renal hypoplasia; severely obstructed urinary tract; idiopathic arterial calcification; congenital rubella syndrome; hemolytic uremic syndrome; very low birth weight (VLBW) infants – low renal mass, impaired nephrogenesis, or nephrocalcinosis.
Cardiovascular: Coarctation of the aorta; distal aortic thrombosis (particularly if a UAC has been in place); fluid overload; vascular stiffness (example in IUGR).
Endocrine: Congenital adrenal hyperplasia; hyperaldosteronism; hyperthyroidism; adrenal hemorrhage; hypercalcemia; hyperthyroidism.
Chronic Lung Disease: May present later, sometimes after NICU discharge.
Medications: Steroids; adrenergic agents; total parenteral nutrition (TPN) leading to salt/water overload or hypercalcemia.
Neurological: Pain; seizures; intracranial hypertension; drug withdrawal; hypoxic-ischemic encephalopathy (HIE).
References
Dionne JM, Abitbol CL, Flynn JT. Hypertension in infancy: diagnosis, management and outcome. Pediatr Nephrol. 2012 Jan;27(1):17-32. doi: 10.1007/s00467-010-1755-z. Epub 2011 Jan 22. Erratum in: Pediatr Nephrol. 2012 Jan;27(1):159-60. PMID: 21258818.
Sehgal, A., Elsayed, K., Nugent, M. et al. Sequelae associated with systemic hypertension in infants with severe bronchopulmonary dysplasia. J Perinatol 42, 775–780 (2022). https://doi.org/10.1038/s41372-022-01372-y
Reyes-Hernandez ME, Bischoff AR, Giesinger RE, Rios DR, Stanford AH, McNamara PJ. Echocardiography Assessment of Left Ventricular Function in Extremely Preterm Infants, Born at Less Than 28 Weeks' Gestation, With Bronchopulmonary Dysplasia and Systemic Hypertension. J Am Soc Echocardiogr. 2024 Feb;37(2):237-247. doi: 10.1016/j.echo.2023.08.013. Epub 2023 Aug 22. PMID: 37619910.
Sehgal A, Krishnamurthy MB, Clark M, Menahem S. ACE inhibition for severe bronchopulmonary dysplasia - an approach based on physiology. Physiol Rep. 2018 Sep;6(17):e13821. doi: 10.14814/phy2.13821. PMID: 30187692; PMCID: PMC6125606.
Stanford AH, Reyes M, Rios DR, Giesinger RE, Jetton JG, Bischoff AR, McNamara PJ. Safety, Feasibility, and Impact of Enalapril on Cardiorespiratory Physiology and Health in Preterm Infants with Systemic Hypertension and Left Ventricular Diastolic Dysfunction. J Clin Med. 2021 Sep 29;10(19):4519. doi: 10.3390/jcm10194519. PMID: 34640535; PMCID: PMC8509219.
Pattnaik P, Shah M, Verma RP. Neonatal Hypertension. [Updated 2025 Sep 15]. In: StatPearls [Internet]. Treasure Island (FL): StatPearls Publishing; 2025 Jan-. Available from: https://www.ncbi.nlm.nih.gov/books/NBK563223/